

# PATHOLOGY FOCUS

December 2020 | Medical Newsletter 12

## Featured articles:

- Inflammatory Bowel Disease: A modern diagnostic perspective
- QuantiFERON-TB Gold Assay for the Diagnosis of Latent Tuberculosis



SEASON'S  
**Greetings**  
*and*  
HAPPY NEW YEAR!

## Season's Greetings and Thank You for your Continued Support Throughout 2020

At the start of 2020, a new decade, never did we imagine we would be changing the way we worked to continue to provide healthcare during a global pandemic. We found ourselves in the same shoes as our patients, concerned about catching this new virus, as we worked quickly on processes for safely managing the health of Australians.

We saw the introduction of Telehealth and electronic pathology request forms, while strict safety protocols were put in place for face-to-face appointments, including social distancing in waiting rooms, regular cleaning, separate collection centres for COVID-19 testing and the wearing of masks/PPE. As we approach the new year, we need to continue to reassure patients that medical centres and collection centres are safe to visit.

In April this year, when the whole of Australia was faced with a stage 4 lockdown, we saw pathology testing numbers drop some 40%. This raised concerns from healthcare professionals on the future health costs of the pandemic, including increased cancer diagnoses. This is still of concern, with no end to the pandemic in sight, and we need to continue to communicate to patients the importance of attending their medical appointments and tests.

With the end of the year quickly approaching, we thank all our referrers for continuing to entrust Clinical Labs with the pathology testing for your patients. We wish you and yours an enjoyable holiday season and a safe and happy New Year. As we await a COVID vaccine, we are here to work together again in 2021, providing the best in healthcare and diagnostics for Australians.

# Inflammatory Bowel Disease: A modern diagnostic perspective

By Associate Professor Louise Smyth

Chronic, diarrhoeal disease of unidentifiable aetiology is described as early as ancient Greek medical tracts and, in retrospect, both Fabry and Morgagni probably described cases prior to Matthew Baillie's 1793 report of lethality of an ulcerative colitis. Following that description, many of the chronic diarrhoeal disorders of unknown aetiology were described as ulcerative colitides. After the description by Sir Samuel Wilks, in 1859, of the autopsy changes found in a 42-year-old woman who died after several months of intractable diarrhoea and fever, the term gained prominence. When Sir William Hale White published a series of cases in 1888, "Ulcerative Colitis" (UC) entered the lexicon. However, a review of Wilks' case using modern diagnostic criteria, would prefer Crohn Disease (CD) but the seminal paper of Burrill Crohn, that differentiated his eponymous, idiopathic, chronic inflammatory disease of the bowel wall, with extra-enteric involvement, did not appear until the October, 1932, edition of JAMA, just 88 years ago, despite several earlier references to the differing patterns of disease and associated pathological findings. Nevertheless, the clinical presentation may not always be clear, especially during the first months of symptoms, and some cases may remain as undifferentiated colitis while others are otherwise resolved. The association between UC and colorectal carcinoma had already been reported, following the introduction of safe sigmoidoscopy, in 1909 by John Lockhart-Mummery. (Mulder, Noble, Justinich, & Duffin, 2014)

The mean Australian annual incidence rate for IBD reported to EpiCom (European Crohn's and Colitis Organization–Epidemiological Committee) in two independent cohorts from 2010 and 2011 was 30.3/100,000 (Vegh. et al. 2014). The prevalence in Australia is expected to increase by approximately 250% from 2010 to 2030. Furthermore, while still predominantly a disease affecting young adults, where the incidence may be reaching a plateau in Western countries (Weimers & Munkholm, 2018), both paediatric and elderly patients are increasingly being diagnosed (Gower-Rousseau, et al., 2013). In addition, these special groups and others may present with different disease phenotypes and require different treatment regimens. In this Northern French population, of similar size to that of Victoria, the incidence rate of CD increased from 5.3 to 7.6 per 10<sup>5</sup> over the study period (1988-2008) while UC remained stable. Strikingly, the incidence of CD in patients under 20 years old nearly doubled, a finding replicated in Italy, Ireland, Scotland and Scandinavia. Importantly, the extent of disease and the inflammatory phenotype was shown to be more severe in younger patients. In fact, the Montreal criteria for the evaluation of adult IBD has been supplemented by the Paris criteria for paediatric disease.

**Table 1 - Montreal and Paris Classifications for Crohn's Disease (CD)**

|                  | Montreal                                                                                                    | Paris                                                                                                                                                                                                                            |
|------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Age at diagnosis | A1: < 17 y<br>A2: 17-40 y<br>A3: > 40 y                                                                     | A1 a: < 10 y<br>A1 b: 10-17 y<br>A2: 17-40 y<br>A3: > 40 y                                                                                                                                                                       |
| Location         | L1: Terminal ileal ± limited cecal disease<br>L2: Colonic<br>L3: Ileocolonic<br>L4: Isolated upper disease* | L1: Distal 1/3 ileum ± limited cecal disease<br>L2: Colonic<br>L3: Ileocolonic<br>L4 a: Upper disease proximal to Ligament of Treitz*<br>L4 b: L4b: Upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum* |
| Behaviour        | B1: Non-stricturing, non-penetrating<br>B2: Stricturing<br>B3: Penetrating<br>P: Perianal disease modifier  | B1: Non-stricturing, non-penetrating<br>B2: Stricturing<br>B3: Penetrating<br>B2B3: Both penetrating and stricturing disease, either at the same or different times<br>P: Perianal disease modifier                              |
| Growth           | n/a                                                                                                         | G0: No evidence of growth delay<br>G1: Growth delay                                                                                                                                                                              |

\*In both the Montreal and Paris Classification systems, L4 and L4a/L4b may coexist with L1, L2, L3, respectively.

(After Levine et al., 2011)

**Table 2 - Montreal and Paris Classifications for Ulcerative Colitis (UC)**

|          | Montreal                                                                                                                 | Paris                                                                                                                                                                 |
|----------|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Extent   | E1: Ulcerative proctitis<br>E2: Left-sided UC (distal to splenic flexure)<br>E3: Extensive (proximal to splenic flexure) | E1: Ulcerative proctitis<br>E2: Left-sided UC (distal to splenic flexure)<br>E3: Extensive (hepatic flexure distally)<br>E4: Pancolitis (proximal to hepatic flexure) |
| Severity | S0: Clinical remission<br>S1: Mild UC<br>S2: Moderate UC<br>S3: Severe UC                                                | S0: Never severe*<br>S1: Ever severe*                                                                                                                                 |

\*Severe defined by Pediatric Ulcerative Colitis Activity Index (PUCAI) ≥65.

(After Levine et al., 2011)

In this French, community-based study, the increased severity of early onset disease was evident despite greater use of immune suppression and biological anti-inflammatories, in this group.

“... clinical symptoms on diagnosis were more subtle in the elderly than in the younger age groups with less diarrhoea, abdominal pain, weight loss, fever and extra-intestinal manifestations (EIMs) in CD and less rectal bleeding and abdominal pain in UC. ... As for phenotypes, elderly onset CD was characterised by the predominance of pure colonic disease (L2) and inflammatory behaviour (B1) in accordance with the literature and in sharp contrast with the youngest age-group. On the other hand, UC location on diagnosis was more alike in the young-onset and elderly onset groups with more extensive disease than in the middle-age group.” (Gower-Rousseau, et al., 2013)

In the same study there was significantly more disease extension, stricturing and perforating behaviour in patients <17 years at diagnosis compared to those >60 years.


Elsewhere, an association with **Primary Immune Deficiency** (especially NOD2 gene & IL10 pathway) has been established in up to 20% of children with very early onset disease (<5 years) and these children should be assessed by a paediatric Clinical Immunologist (Kelsen & Sullivan, 2017). In all age groups, **intestinal infection should be excluded** as a cause of presenting symptoms, especially in high-risk groups but, infection is also an important complication of IBD (especially penetrating

CD) and presents a risk to patients who require immune suppression.

While the aetiology and pathogenesis of IBD remains unclear, it is ever more clear that they represent a complex interaction of genetic susceptibility and environmental factors resulting in abnormal immune responses directed against the gut microbiota of affected individuals. The changing epidemiology, detailed by Kaplan and Windsor (Kaplan & Windsor, 2020), underlines the association with increasing Westernisation/industrialisation. **Diagnosis is predicated upon endoscopy, imaging and histology** but features may change in serial small biopsies of bowel and a significant proportion of diagnoses are only secured after colectomy. **Selection of patients for diagnostic endoscopy or follow-up assessment of disease activity can be enhanced by the measurement of blood and faecal biomarkers, which may also favour one disease over the other, minimising expensive, invasive, higher-risk investigation.** It is especially useful to identify patients without evidence of bowel wall inflammation at presentation, who are more likely to have Irritable Bowel Syndrome (IBS). The usefulness of biomarkers has been established in adults (Kochhar & Lashner, 2017) and in children (Elitsur, Lawrence, & Tolaymat, 2005).

UK Guidelines suggest the following approach to differentiate patients presenting with symptoms that may be attributable to IBD or IBS.

Figure 1 – Use of Faecal Calprotectin Test in Primary Care



(After Lamb, Kennedy, Raine, et al., 2019)

**Table 3 - Usefulness of tests available at Clinical Labs for the assessment of possible or established IBD, other than biopsy.**

| Biomarker                                                       | Source | Clinical Use                                                                                                                                                                                                                                | Sensitivity      | Specificity                                                                                           |
|-----------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------------------|
| Acute phase reactants                                           |        |                                                                                                                                                                                                                                             |                  |                                                                                                       |
| CRP                                                             | Blood  | General measure of systemic inflammation. CRP increased in most with active inflammation. CD > UC.                                                                                                                                          | High             | Low                                                                                                   |
| ESR                                                             | Blood  | General measure of systemic inflammation. ESR peaks and decreases slower than CRP. May be better at monitoring disease activity/response to treatment after the first 24 hours of onset while CRP may be more useful in the first 24 hours. | High             | Low                                                                                                   |
| Antibodies                                                      |        | Best used in combination.                                                                                                                                                                                                                   |                  |                                                                                                       |
| Anti-Saccharomyces cerevisiae antibodies (ASCA)                 | Blood  | Adults and children with CD.                                                                                                                                                                                                                | Low to moderate  | Moderate to high                                                                                      |
| Anti-perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) | Blood  | Adults and children with UC.                                                                                                                                                                                                                | Moderate to high | Low to moderate                                                                                       |
| ASCA+/pANCA-                                                    | Blood  | Favour CD in clinical IBD.                                                                                                                                                                                                                  | Moderate         | High                                                                                                  |
| ASCA-/pANCA+                                                    | Blood  | Favour UC in clinical IBD.                                                                                                                                                                                                                  | Moderate         | High                                                                                                  |
| Calprotectin                                                    | Faeces | IBD versus IBS. Activity of IBD & postoperative recurrence of CD.                                                                                                                                                                           | High             | Moderate. Measures granulocyte-mediated inflammation in the bowel wall. RI varies by age in children. |

**References**

Elitsur, Y., Lawrence, Z. B., & Tolaymat, N. (2005, September). The Diagnostic Accuracy of Serologic Markers in Children with IBD: the West Virginia Experience. *Journal of Clinical Gastroenterology*, 39(8), 670-673. doi:10.1097/01.mcg.0000173853.78-42.2d

Gower-Rousseau, C., Vasseur, F., Fumery, M., Savoye, G., Salleron, J., Dauchet, L., . . . Colombel, J. (2013, February). Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD). *Digestive and Liver Disease*, 45(2), 89-94. Retrieved from https://doi.org/10.1016/j.dld.2012.09.005

Kaplan, G. G., & Windsor, J. W. (2020). The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology*. Retrieved from https://doi.org/10.1038/s41575-020-00360-x

Kelsen, J. R., & Sullivan, K. E. (2017, July 28). Inflammatory Bowel Disease in Primary Immunodeficiencies. *Current Allergy and Asthma Reports*, 17. Retrieved from https://doi.org/10.1007/s11882-017-0724-z

Kochhar, G., & Lashner, B. (2017, January 30). Utility of Biomarkers in the Management of Inflammatory Bowel Disease. *Current Treatment Options in Gastroenterology*, 15, 105-115. Retrieved from https://doi.org/10.1007/s11938-017-0129-z

Lamb, C. A., Kennedy, N. A., Raine, T., & et al. (2019, September 27). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*, 68, s1-s106. Retrieved from http://dx.doi.org/10.1136/gutjnl-2019-318484

Mulder, D. J., Noble, A. J., Justinich, C. J., & Duffin, J. M. (2014, May 1). A tale of two diseases: The history of inflammatory bowel disease. *Journal of Crohn's and Colitis*, 8(5), 341-348. Retrieved from https://doi.org/10.1016/j.crohns.2013.09.009

Vegh, Z., & et al. (2014, November 1). EpiCom-group, Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. *Journal of Crohn's and Colitis*, 8(11), 1506-1515. Retrieved from https://doi.org/10.1016/j.crohns.2014.06.004

Weimers, P., & Munkholm, P. (2018, January 23). The Natural History of IBD: Lessons Learned. *Current Treatment Options in Gastroenterology*, 16, 101-111. Retrieved from https://doi.org/10.1007/s11938-018-0173-3




**Simplifying how you order pathology**

The upgraded version of eOrders, available for all practices using MedicalDirector Clinical 3.18+, will save you time when ordering pathology by:

- Using a predictive search function
- Intelligently predicting your preferred test combinations
- Suggesting additional tests based on the latest recommendations

Visit [clinicallabs.com.au/eorders](https://clinicallabs.com.au/eorders) for instructions on how to upgrade today!




## Follow-up on Coeliac Disease (CD) Testing

Once a proband has been identified it is important to screen asymptomatic first-degree relatives (or other close relatives who may have symptoms). There are two schools of thought regarding the best screening of first degree relatives. Initial screening for susceptibility by HLA DQ2/8 identification has been shown to be cost-effective compared to repeated autoantibody testing and endoscopy for asymptomatic individuals. HLA DQ testing is done once and patients who have neither antigen should only be further investigated for CD under specialist management.



The European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) has issued guidelines, updated in 2019. According to their recommendations:

1. If CD is suspected, measurement of total serum IgA and IgA-antibodies against transglutaminase 2 (anti-tTG) is superior to other combinations.
2. If total IgA is low/undetectable, an IgG based test is indicated. (ACL routinely tests for IgG antibodies against deamidated gliadin peptide for initial testing.)
3. If anti-tTG -IgA is  $\geq 10$  times the upper limit of normal and the family agrees, the no-biopsy diagnosis may be applied, provided endomysial antibodies (EMA-IgA) test positive in a second blood sample and patients with positive results have been referred to a paediatric gastroenterologist/specialist.
4. Patients with no/mild histological changes but confirmed autoimmunity should be followed closely.



In addition, the American College of Gastroenterology Clinical Guideline: Diagnosis and Management of Celiac Disease recommends that in children younger than 2 years of age for CD, the IgA tTG test should be combined with deamidated gliadin peptide.

Autoantibody levels should always be tested while patients are taking a gluten-containing diet as the concentration of antibodies has been shown to disappear or fall to near-negative levels within 12-18 months of strict adherence to a gluten-free diet. Although it is not possible to definitively correlate villus healing with the disappearance of serological markers, retesting of serology should occur at least at 6 and 12 months after diagnosis, and yearly thereafter, unless symptoms recur or there are complications.

### Reference

Horwitz, A *et al.* "Screening for celiac disease in Danish adults." *Scand J Gastroenterol*, 2015; 50(7): 824–831.

Husby, S *et al.* "European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2019." *Journal of Pediatric Gastroenterology and Nutrition*, (Ahead of Print).

Rubio-Tapia, A *et al.* "ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease."

*American Journal of Gastroenterology*. 108(5):656–676, May 2013.

Caio, G *et al.* "Celiac disease: a comprehensive current review." *BMC medicine* vol. 17,1 142. 23 Jul. 2019, doi:10.1186/s12916-019-1380-z

## About the author:



## Assoc. Professor Louise Smyth

BA MBBS GCUT DipHPE FRCPA

**Lab:** Osborne Park

**Speciality:** Allergy and Immunology

**Areas Of Interest:** Autoimmunity, transplantation, immune deficiency, allergy

**Phone:** 1300 367 674

**Email:** Louise.Smyth@clinicallabs.com.au

Associate Professor Smyth is a graduate of the University of Western Australia and a Fellow of, and former state representative of the RCPA. Associate Professor Smyth designed and implemented the Pathology programme for the School of Medicine at the University of Notre Dame Australia, Fremantle where she is a founding member of, and Associate Professor in the School of Medicine. She has a Graduate Certificate in University Teaching, qualifying her to supervise candidates for higher degrees as well as teaching undergraduate students. She is most interested in autoimmunity but has extensive experience including autoimmunity, transplantation, immune deficiency and allergy. Her publications are predominantly in the field of Bone Marrow Transplantation. Dr Smyth joined St John of God Pathology (now Australian Clinical Labs) in 2016.

# QuantiFERON-TB Gold Assay for the Diagnosis of Latent Tuberculosis

By Associate Professor Owen Harris



Interferon Gamma Release Assays (IGRA)s are in vitro blood tests of the cell-mediated immune system. The QuantiFERON-TB Gold (QFT) assay is an IGRA measuring T-cell release of IFN- $\gamma$  following stimulation by antigens specific to Mycobacterium tuberculosis complex.

## The test

The QFT assay consists of four tubes: the negative-control (nil) tube that measures background IFN, a positive control (mitogen) tube with a non-specific stimulant and two antigen tubes (TB1 and TB2) for diagnosis of latent M. tuberculosis infection.

TB1 contains peptides from the specific Mycobacterium tuberculosis antigens ESAT-6 and CFP-10 designed to elicit an immune response from CD4+ T-helper lymphocytes.

TB2 contains an additional set of peptides targeting a cell-mediated immune response from CD8+ cytotoxic T lymphocytes.

The four tubes are filled with a set amount of whole blood and incubated. During incubation, the antigens stimulate lymphocytes to produce interferon, which is measured by an enzyme immunoassay.



## Performance

Since there is no gold standard for latent tuberculosis infection (LTBI), sensitivity and specificity are typically estimated using surrogate reference standards.

Sensitivity is estimated among culture-confirmed TB cases, while specificity is estimated among low-risk individuals with no known TB exposure in low-incidence settings.

## Use in children

Due to differences in immune function in young children, (<5 years), QuantiFERON-TB Gold is unreliable and should not be used in this age group.

## Interpretation of results

According to the manufacturer, the test is interpreted as positive when either antigen tube result is positive ( $\geq 0.35$  u/l).

The medical literature, supported by case review experience at Clinical labs, indicates that in a low prevalence population, there is a high rate of false positive (non-specific) results when either TB1, TB2 or both are in the low positive range of 0.35 to 0.70 u/l.

Results in this range need to be carefully correlated with clinical findings and epidemiological risk before making a diagnosis of latent tuberculosis.



Calcified nodules in the left upper lobe, consistent with latent tuberculosis.

## Indications for treatment of latent tuberculosis

The decision to treat latent TB, to prevent progression to active TB, depends on:-

The pre-test probability, in particular immigrants and expatriates, including health care workers, from countries with a high TB prevalence.

The risk of progression to active TB: 50% of the lifetime risk of progression occurs within the first 2 years of primary infection. Age-related risks are seen in infants (50%), children (12-25%) and adolescents (10-20%).

Groups with >5 times risk include patients with HIV infection, children <5 years, patients receiving TNF- $\alpha$  inhibitors, patients with a history of untreated or inadequately treated TB and patients with silicosis, chronic renal failure, leukaemia, lymphoma, or cancer of the upper or lower respiratory tract.

Groups with 1-5 times risk include patients post gastrectomy, with malnutrition, cigarette smokers, abusers of alcohol and drugs, patients with diabetes mellitus and immunosuppression with agents such as prednisolone (>15 mg daily).

Efficacy of treatment requires adherence to treatment for up to 9 months. The risk of side effects such as hepatitis (aggravated by age, pre-existing liver disease and alcohol), peripheral neuritis or allergy requires consideration.

A useful reference is Management of tuberculosis: a guide for clinicians, by Denholm JT, Eisen DP, Fox G, McBryde ES, Street A., published by Greenhill Publishing, 2017. ISBN 97890648137979.

## About the author



## Assoc. Professor Owen Harris

**MBBS, FRCPA**

**Lab:** Geelong

**Areas Of Interest:** General microbiology and microbiological molecular diagnostics, Q fever and infectious serology.

**Speciality:** Microbiology

**Phone:** (03) 5225 1144

**Email:** Owen.Harris@clinicallabs.com.au




Associate Professor Harris is Clinical Director of Microbiology at Australian Clinical Labs. He graduated in Medicine from Monash University in 1971 and completed his training at Geelong Hospital, obtaining FRCPA in 1982. Associate Professor Harris worked in general pathology at Geelong Pathology followed by PathCare as Consulting Pathologist. For the past 20 years, he has been a Clinical Microbiologist, providing support for infection control and antimicrobial stewardship services at various hospitals. Associate Professor Harris has collaborated on many research projects with the Department of Infectious Diseases at Barwon Health and worked on Q fever outbreak investigations. He is involved in undergraduate and postgraduate teaching including supervision of infectious diseases/microbiology registrar training with Barwon Health. In 2015, Associate Professor Harris was appointed Senior Clinical Lecturer and Clinical Associate Professor at Deakin University.

# Missed an issue of Pathology Focus?

Catch up on past editions of Pathology Focus by visiting the Newsletter Archive on our website [clinicallabs.com.au/newsletters](http://clinicallabs.com.au/newsletters). Our medical newsletters feature clinical content written by our expert pathologists and key external contributors on new and topical pathology tests and associated health conditions.

## Some of our past articles not to be missed:

- Fertility Testing (September 2020)
- Melanoma (February 2020)
- Aspect Liquid Biopsy (October 2019)
- Vitamin D (September 2019)
- Urea Breath Testing (July 2019)
- STI Testing (October 2018)



Get the next edition of our newsletter delivered straight to your Inbox. Go to [clinicallabs.com.au/subscribe](http://clinicallabs.com.au/subscribe) and follow the instructions.

## Latest News: Clinical Labs is now Offering COVID-19 Testing for Travellers

Many countries are requesting that international travellers complete a COVID-19 PCR and/or Antibody Test before boarding their flight.

Clinical Labs is now offering travellers the ability to purchase the below COVID-19 tests for travel through our secure web portal ([store.clinicallabs.com.au](https://store.clinicallabs.com.au)).

- o COVID-19 PCR Test for Travel
- o Combined COVID-19 PCR & Antibody (IgG and IgM) Test

These tests are for asymptomatic travellers only. No Medicare rebate is available.

### Travellers can order a test by:

- ✔ Visiting [store.clinicallabs.com.au](https://store.clinicallabs.com.au) where they create an account, and order and pay for their test.
- ✔ Travellers are then sent a confirmation email that contains their receipt/referral.
- ✔ They need to print this and take it with them to a **Clinical Labs Travel Collection Centre** (see [clinicallabs.com.au/travel](https://clinicallabs.com.au/travel) for listing), along with a form of photo ID (passport or driver's licence).
- ✔ After completing the test, their sample will be processed within 24 hours and they will be sent an SMS notification when their result is ready.
- ✔ Travellers then log back into [store.clinicallabs.com.au](https://store.clinicallabs.com.au) where they can view their result by downloading a pdf and print this as required by the relevant travel authority.



## eResults


### Saving you time by simplifying the way you access patients' results.

Clinical Labs' eResults is a secure and intuitive web portal that provides referrers with access to patients' pathology results 24 hours a day. Our new, upgraded version of eResults is a major step up in terms of usability, with a much **faster, easier and smarter** interface. If you already have an eResults username and password, then you can log in and start using the new eResults today.

### The features of our upgraded eResults web portal include:

- An intuitive design that highlights recent and unread patient results
- Quicker and more intelligent search for patients and tests
- Single-click episode view: Ability to view all results at once for a patient episode
- Cumulative view: For a particular test, see the complete patient history on the one screen
- Provider-based search: Use a drop-down menu to filter results by provider/clinic
- Choose to sort results by: "Date collected", "Date ordered" or the most recent report "Date updated"
- Ability to print specific panels across multiple patient episodes

- Option to print a simplified, snapshot report, without comments and additional information
- Adaptable to different device screen sizes – mobile, tablet, laptop and desktop screens



To start using the new eResults today, visit [clinicallabs.com.au/results](https://clinicallabs.com.au/results)

Or, to register, visit [clinicallabs.com.au/register/eHealth](https://clinicallabs.com.au/register/eHealth)

For any questions, please call our friendly eHealth Support Team on 1300 669 961 (or 1300 367 674 for WA).

NEW

To receive our bi-monthly clinical newsletter, updates, educational resources and more, go to [clinicallabs.com.au/subscribe](https://clinicallabs.com.au/subscribe) and follow the instructions.






2020-2022 TRIENNIUM



# Skin Excision Evaluation Program

*Join thousands of general practitioners nationwide and earn your CPD points while improving your clinical skills*

To register today simply email [skinaudit@clinicallabs.com.au](mailto:skinaudit@clinicallabs.com.au)



 PROFESSIONAL DEVELOPMENT PROGRAM  
ACCREDITED ACTIVITY 2020 - 2022

 RACGP | CPD Education Provider 

# Subscribe to our electronic mailing list

Subscribe to the Clinical Labs mailing list and receive our bi-monthly clinical newsletter, important updates, educational resources and more, delivered directly to your inbox. Simply visit [clinicallabs.com.au/subscribe](http://clinicallabs.com.au/subscribe) and follow the instructions.

Alternatively, complete the form below, tear along the perforated edge and fax it to Clinical Labs on **(03) 9538 6733**

Title

Given Name

Surname

Email

Practice Name

Practice Address

Practice Suburb

Post Code

Please tick one of the below:

- General Practitioner
- Specialist
- Medical Centre / Practice Manager

**Thank you**